

RECORDATI: BOARD APPROVES A SUPPLEMENT TO THE AGENDA OF THE ANNUAL MEETING OF SHAREHOLDERS

Milan, 14 March 2013 – Recordati's Board of Directors approved the following supplement deliberation proposal to be submitted to the Annual Meeting of Shareholders convened for 17 April 2013, the sole convocation date: "appointment of a new director after first changing the number of directors. Relative and consequent resolutions".

Further information will be provided in the Directors' report which will be made available at the Company's head office and published on the Company's website (www.recordati.com) within the terms of law.

For easy of reference, please find here below the complete agenda of the above mentioned Annual Meeting of Shareholders, as consequently supplemented:

1. Board of Directors' Review of Operations; Report of the Board of Statutory Auditors; Financial Statements as at and for the financial year ended 31st December 2012; relative and consequent resolutions.
2. Remuneration policies in accordance with article 123-ter of Legislative Decree No. 58/98; relative and consequent resolutions.
3. Proposal to authorise the purchase and utilization of treasury stock; relative and consequent resolutions.
4. Proposal to approve regulations for shareholders' meetings.
5. Appointment of a new director after first changing the number of directors. Relative and consequent resolutions.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Central and Eastern Europe, and in Turkey. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses from companies which do not have a European presence. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Ketchum
Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com
Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832